Home β€Ί Stock analysis β€Ί OGN

Organon (OGN) Stock: Why It's Up Today

Updated Oct 20, 2026, 11:31 AM ET Β· intraday price

What changed since yesterday

OGN rises 0.3% to $13.80. Trading at $13.80 (intraday, 11:31 AM ET), +0.33% vs the prior close of $13.75. Day range $13.75–$13.80, opened at $13.75.

Price (intraday)$13.80+0.33%
Day range13.75–13.80
Open13.75
Volume515.61K
52-week range5.69–13.83
Avg volume (20d)2.04M

OGN daily analysis β€” what happened

A plain-English, data-only note for every US trading day (today's note updates every 2 hours while the market is open). Newest first; older days stay archived below.

Oct 20, 2026 β€” OGN rises 0.3% to $13.80
Oct 19, 2026 β€” OGN ends flat (-0.1%) to $13.75
Oct 16, 2026 β€” OGN ends flat (+0.0%) to $13.76
Oct 15, 2026 β€” OGN ends flat (+0.1%) to $13.76
Oct 14, 2026 β€” OGN ends flat (-0.2%) to $13.74, 3 down days in a row
Oct 13, 2026 β€” OGN ends flat (+0.0%) to $13.77
Oct 12, 2026 β€” OGN ends flat (-0.3%) to $13.77
Oct 9, 2026 β€” OGN rises 0.4% to $13.81, a 52-week high
Oct 8, 2026 β€” OGN ends flat (-0.3%) to $13.75
Oct 7, 2026 β€” OGN rises 0.4% to $13.79, a 52-week high
Oct 6, 2026 β€” OGN ends flat (+0.3%) to $13.74
Oct 5, 2026 β€” OGN ends flat (-0.1%) to $13.70
Oct 2, 2026 β€” OGN ends flat (+0.1%) to $13.72

OGN bull case vs bear case (from the data)

Bull case
  • Price is +0.5% vs its 50-day average β€” short-term trend is up.
  • Price is +22.2% vs its 200-day average β€” above the long-term trend line.
  • Latest fiscal-year net income: profit of $187.00M.
  • Insiders made 8 open-market purchases in the last 12 months.
Bear case
  • Annual revenue fell 2.9% in the latest fiscal year (SEC XBRL).

OGN latest news & SEC filings

Every SEC filing by or about OGN in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.

Aug 14, 2026 Β· Form SCHEDULE 13G β€” Passive stake (13G)

Passive stake (13G) β€” an investor reported owning more than 5%

Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.

Source: SEC EDGAR filing 0000919574-26-005523

Aug 12, 2026 Β· Form 4 β€” Insider trade

Insider trade report (Form 4) β€” a director, officer or 10%+ owner changed their holdings

Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).

Source: SEC EDGAR filing 0001628280-26-056061

Aug 5, 2026 Β· Form 144 β€” Planned insider sale

Notice of proposed sale (Form 144) β€” an insider or affiliate plans to sell restricted or control shares

A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.

Source: SEC EDGAR filing 0001950047-26-007707

Aug 5, 2026 Β· Form 4 β€” Insider trade

Insider trade report (Form 4) β€” a director, officer or 10%+ owner changed their holdings

Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.

Source: SEC EDGAR filing 0001628280-26-053306

Jul 31, 2026 Β· Form SCHEDULE 13G/A β€” Update to a passive 5%+ stake (13G)

Update to a passive 5%+ stake (13G)

Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.

Source: SEC EDGAR filing 0002100121-26-000905

Jul 31, 2026 Β· Form 8-K β€” Major event / current report

Current report β€” a filing companies must make within 4 business days of a major event

Source: SEC EDGAR filing 0001104659-26-089008

Jul 31, 2026 Β· Form 10-Q β€” Quarterly report

Quarterly report (unaudited financial statements for the quarter)

Quarter ended Jun 30, 2026:

Source: SEC EDGAR filing 0001628280-26-051230

Jul 23, 2026 Β· Form 8-K β€” Major event / current report

Current report β€” a filing companies must make within 4 business days of a major event

Source: SEC EDGAR filing 0001193125-26-314587

Jul 17, 2026 Β· Form DEFA14A β€” Additional proxy materials

Additional proxy materials

Source: SEC EDGAR filing 0001193125-26-307830

Jul 17, 2026 Β· Form 8-K β€” Major event / current report

Current report β€” a filing companies must make within 4 business days of a major event

Source: SEC EDGAR filing 0001193125-26-307767

Things to know before you trade OGN

OGN market data (last 20 sessions)

DateOpenHighLowCloseVolume
Oct 20, 202613.7513.8013.7513.80515.61K
Oct 19, 202613.7713.7713.7213.753.25M
Oct 16, 202613.7713.7813.7413.762.65M
Oct 15, 202613.7513.7713.7513.761.98M
Oct 14, 202613.7713.7713.7413.741.81M
Oct 13, 202613.7713.7913.7613.772.89M
Oct 12, 202613.8013.8013.7613.77932.30K
Oct 9, 202613.7613.8313.7513.813.26M
Oct 8, 202613.7813.8013.7513.752.09M
Oct 7, 202613.7213.7913.7213.792.21M
Oct 6, 202613.7413.7513.7313.741.95M
Oct 5, 202613.7213.7513.7013.702.88M
Oct 2, 202613.7113.7513.7113.721.92M
Oct 1, 202613.7113.7413.7113.712.10M
Sep 30, 202613.7413.7613.7013.702.07M
Sep 29, 202613.7313.7513.7213.741.63M
Sep 28, 202613.7513.7513.7213.731.99M
Sep 25, 202613.7413.7413.7013.731.39M
Sep 24, 202613.7213.7413.7213.722.22M
Sep 23, 202613.7113.7413.7013.73983.30K

About Organon

Organon (OGN) is listed on the NYSE and classified by the SEC under β€œPharmaceutical Preparations”. Its business address is in JERSEY CITY, NJ. Fiscal year ends December 31. SEC CIK 1821825.

OGN board of directors & executives

From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).

Directors

NameRoleLatest filing
Carrie Smith CoxExecutive ChairNov 13, 2025
Robert EssnerDirectorJun 15, 2026
Alan EzekowitzDirectorJun 15, 2026
Helene D GayleDirectorJun 15, 2026
Rochelle B LazarusDirectorJun 15, 2026
Deborah R LeoneDirectorJun 15, 2026
Philip OzuahDirectorJun 15, 2026
Cynthia M PattonDirectorJun 15, 2026
Ramona SequeiraDirectorJun 15, 2026
Shalini SharpDirectorJun 15, 2026

Executive officers

NameTitleLatest filing
Ferreira Juan Camilo ArjonaHead of R&D & CMOAug 12, 2026
Carrie Smith CoxExecutive ChairNov 13, 2025
Juliana Papa DrinaneHead of Mfg & SupplyAug 5, 2026
Aaron FalcioneChief Human Resources OfficerApr 2, 2026
Lynette HolzbaurSVP and Corporate ControllerMay 7, 2026
Daniel KarpExecutive VP, Corp. Dev.Apr 2, 2026
Joseph T. Jr. MorrisseyInterim CEOApr 2, 2026
Vittorio NisitaHead of Global Business SvcsApr 2, 2026
Rachel A StahlerChief Information OfficerApr 2, 2026
Matthew M WalshChief Financial OfficerApr 2, 2026
Kirke WeaverGen. Counsel & Corp. Secy.Apr 2, 2026

Recent insider buys & sales

DateInsiderTypeSharesPrice
Aug 5, 2026Juliana Papa DrinaneSale14,761$13.57
Aug 5, 2026Juliana Papa DrinaneSale14,761$13.57
Aug 5, 2026Juliana Papa DrinaneSale14,761$13.57
Aug 5, 2026Juliana Papa DrinaneSale14,761$13.57
May 6, 2026Lynette HolzbaurSale26,448$13.35
May 6, 2026Lynette HolzbaurSale26,448$13.35
May 6, 2026Lynette HolzbaurSale26,448$13.35
May 6, 2026Lynette HolzbaurSale26,448$13.35
May 6, 2026Lynette HolzbaurBuy26,448$13.35
May 6, 2026Lynette HolzbaurBuy26,448$13.35
May 6, 2026Lynette HolzbaurBuy26,448$13.35
May 6, 2026Lynette HolzbaurBuy26,448$13.35
Nov 12, 2025Carrie Smith CoxBuy65,400$7.67
Nov 12, 2025Carrie Smith CoxBuy65,400$7.67
Nov 12, 2025Carrie Smith CoxBuy65,400$7.67

OGN financials (annual, from XBRL filings)

Fiscal year endRevenueNet incomeDiluted EPSOperating cash flow
Dec 31, 2025$6.22B$187.00M0.72$700.00M
Dec 31, 2024$6.40B$864.00M3.33$939.00M
Dec 31, 2023$6.26B$1.02B3.99$799.00M
Dec 31, 2022$6.17B$917.00M3.59$858.00M
Dec 31, 2021$6.30B$1.35B5.31β€”

Latest balance sheet: total assets $13.18B, total liabilities $12.17B, cash $1.13B (as of Jun 30, 2026).

OGN earnings / results-day log

DateFilingClose that day
Apr 30, 20268-K Item 2.02 (results)$13.25
Feb 12, 20268-K Item 2.02 (results)$7.06
Nov 10, 20258-K Item 2.02 (results)$7.71
Aug 5, 20258-K Item 2.02 (results)$8.40
May 1, 20258-K Item 2.02 (results)$9.45
Feb 13, 20258-K Item 2.02 (results)$16.32
Oct 31, 20248-K Item 2.02 (results)$18.78
Aug 6, 20248-K Item 2.02 (results)β€”
May 2, 20248-K Item 2.02 (results)β€”
Feb 15, 20248-K Item 2.02 (results)β€”
Nov 2, 20238-K Item 2.02 (results)β€”
Aug 8, 20238-K Item 2.02 (results)β€”

Related stocks Β· Pharmaceutical Preparations

Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Regeneron Pharmaceuticals (REGN)Novo Nordisk A S (NVO)

Popular today

Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)Tesla (TSLA)Space Exploration Technologies (SPCX)Apple (AAPL)AMD (AMD)Microsoft (MSFT)Intel (INTC)Amazon (AMZN)

More on OGN

Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: intraday data as of Oct 20, 2026, 11:31 AM ET. Filings: SEC EDGAR. Refreshed every 2 hours during US market hours.